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OBJECTIVES We hypothesized that plasma factors important for the development of atherosclerosis play a
major role in the occurrence of cardiac allograft vasculopathy (CAV).
BACKGROUND Cardiac allograft vasculopathy is a major cause of death among heart transplant recipients, has
a poorly understood pathogenesis and has similarities to atherosclerotic coronary disease.
METHODS The study population consisted of 93 postcardiac transplant recipients. Thirty-one patients
with congestive heart failure (CHF) and 18 healthy individuals served as control subjects.
Posttransplant coronary anatomy was evaluated by angiography and intravascular ultrasound.
Laboratory analyses of lipids, homocysteine, vitamin B12 and folate, fibrinogen, vonWill-
ebrand factor antigen (vWFAg) and renin were obtained on all participants.
RESULTS Posttransplant patients were found to have elevated serum triglycerides, total cholesterol/
high-density lipoprotein cholesterol ratio, lipoprotein (a), homocysteine, vWFAg, fibrinogen
and renin and lower high-density lipoprotein cholesterol. Most of these laboratory athero-
genic factors were also elevated to a similar degree in the CHF control population.
Although most atherogenic markers were elevated, there was little correlation with CAV
severity. Cardiac allograft vasculopathy severity varied with time after transplantation,
3-hydroxy-methyl-glutaryl-coenzyme A reductase inhibitor use and prior cytomegalovirus
infection. Even within the normal range, lower RBC folate levels were associated with
increased severity of CAV.
CONCLUSIONS The posttransplant course is associated with increased clinical and laboratory atherogenic
factors, some of which likely contribute to the severity of coronary vasculopathy. Compared
with normal control subjects, many of these markers are already increased in pretransplant
CHF patients with or without occlusive coronary artery disease. (J Am Coll Cardiol 2000;36:
509–16) © 2000 by the American College of Cardiology
Cardiac allograft vasculopathy (CAV) is the major cause of
late death among heart transplant recipients. The patho-
genesis of CAV has been described as an accelerated form of
coronary artery disease (CAD) with similarities to tradi-
tional atherosclerosis (1–7). Atherosclerotic plaque can be
present in CAV, but the spectrum of histopathologic
findings suggests a multifactorial process. The “response to
injury” hypothesis regarding the pathogenesis of atheroscle-
rotic disease is also believed to apply to CAV (1–10), in
which immunologic and nonimmunologic factors produce
myointimal proliferation in response to endothelial injury.
Early intimal proliferation is characteristic of CAV and
progresses with varying degrees of lipid deposition (3,4,9).
Histopathological studies of CAV demonstrate that, in
contrast to atherosclerotic diseases, the internal elastic
lamina is typically intact, calcification is rare, and the disease
tends to develop rapidly (months to years vs. years to
decades, respectively) (1–5).
We hypothesized that, despite the unique features of
CAV, plasma factors important for the development of
atherosclerotic coronary disease also play a major role in the
occurrence of CAV. We, therefore, conducted this con-
trolled study to further examine the relationships between
various plasma atherogenic factors and CAV in cardiac
transplant patients.
METHODS
Study populations. This investigation was approved by the
Institutional Review Board for Human Studies at The Ohio
State University, and written, informed consent was ob-
tained from each subject before enrollment. The study
population consisted of 93 postcardiac transplant patients
who presented consecutively for routine clinical follow-up,
cardiac catheterization and myocardial biopsy. Thirty-one
consecutive congestive heart failure (CHF) patients, all New
York Heart Association (NYHA) functional class III or IV
being evaluated as transplant candidates, were enrolled from
The Ohio State University CHF clinic as a CHF control
group. These patients were matched with the transplant
patients in terms of age, gender and presence or absence of
CAD. In addition, 18 age- and gender-matched individu-
als, free of medication and known illness, served as a
healthy, normal control group.
Three posttransplant patients were excluded from further
analysis because recent coronary angiography or ultrasound
was not available. Diagnostic catheterization with coronary
angiography was performed on 74 of 90 (82%) patients
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within six months of study enrollment, with the majority
occurring within four days (40/74; 54%). Four additional
patients were retained because their last angiograms were
obtained within 10 months of enrollment. Seven patients
were included without angiographic data but were assigned
to the “non-CAV” category because they were recent (,1
year) recipients of young (,40 years old) donor hearts. Five
patients had their last coronary angiograms performed
between nine and 18 months before enrollment but had
established CAV in the severe category and were considered
unlikely to have improved to the mild status of CAV.
Laboratory assessment of blood samples. Venous blood
samples (30–40 ml) were obtained after an overnight fast of
over 12 h, before AM medications and after supine position-
ing for .30 min. Total cholesterol, high-density lipoprotein
(HDL) cholesterol and triglyceride levels were measured by
reflectance spectrophotometry with a Johnson & Johnson
Vitros 950. Low-density lipoprotein (LDL) cholesterol was
calculated via the Friedwald equation (11). Serum apoli-
poprotein A and apolipoprotein B levels were measured by
automated immunoprecipitin analysis using Antibody Re-
agent Set II: SPQ Test System (Incstar Corporation,
Stillwater, Minnesota) and serum lipoprotein (a) (Lp[a])
levels by automated immunoprecipitin analysis using the
Antibody Reagent Set: SPQ Test System (Incstar Corpo-
ration, Stillwater, Minnesota). Serum homocysteine con-
centration was analyzed by gas chromatography/mass spec-
trometry (Metabolite Labs, Denver, Colorado) (12). Serum
Vitamin B12 and folate and RBC folate were measured with
the ACS:180 kit (Chiron Diagnostics, East Walpole, Mas-
sachusetts), utilizing a competitive assay (B12) and immu-
noassay (folate). Renin levels were determined by radioim-
munoassay (Incstar Corporation, Stillwater, Minnesota).
Fibrinogen was measured via clot detection/modified Clauss
method. Von Willebrand factor antigen (vWFAg) was
determined by enzyme immunoassay (Asserachrom vWF,
American Bioproducts Corporation, Parsippany, New Jer-
sey).
Assessment of coronary arteries. Biplane coronary an-
giography and intracoronary ultrasound (ICUS) were per-
formed per standard technique as a part of the annual
posttransplant evaluation (13–23). The coronary angio-
grams (six or more planes) were independently evaluated by
three cardiologists (G.E.C., G.M.E., C.V.L.) blinded to
results of other laboratory analyses. Coronary anatomy was
categorized into three CAV subgroups based on the severity
of epicardial coronary disease and distal vessel attenuation.
The epicardial coronary disease was defined as normal/
insignificant if ,50% stenosis was present in any epicardial
vessel and significant if stenosis was .50%. Distal vessels
were defined as the distal one-third of the major epicardial
coronary arteries, the distal half of their primary branch
vessels and all tertiary vessels; their attenuation was graded
as none, mild or moderate-severe. Cardiac allograft vascu-
lopathy status was then defined as “non-CAV” (insignificant
epicardial disease with no distal vessel attenuation), “mild-
CAV” (insignificant epicardial disease with mild distal
vessel attenuation) or “severe-CAV” (significant epicardial
disease or moderate-severe distal vessel attenuation). Agree-
ment between at least two of three readers was required for
final classification. Intracoronary ultrasound was obtained in
only 37 patients because of patient preference, and ICUS-
derived intimal thickness index was determined as previ-
ously reported (15). The respective intimal thickness index
of the epicardial coronary arteries in each CAV subgroup
was 20 6 14%, 27 6 15%, and 34 6 15% for non-CAV,
mild-CAV and severe-CAV (p , 0.05).
Statistical analysis. All samples and data were coded to
maintain blinded analyses. One-way analysis of variance was
used to compare mean values of clinical and demographic
data between healthy controls, CHF controls and posttrans-
plant patients (non-CAV, mild-CAV and severe-CAV).
Tukey’s Honestly Significant Difference test was used to
investigate pairwise differences for factors, which displayed
an overall significant difference between groups. However,
when the distributions exhibited nonnormality, the
Kruskal-Wallis test was utilized as a nonparametric alter-
native to assess overall significance. Pairwise comparisons
were then made by performing the Wilcoxon Rank Sum
Test. All data are presented as mean 6 one standard
deviation.
RESULTS
Characteristics of the study populations. The three
groups were well-matched for age, race and gender (Table
1). The prevalence of diabetes mellitus was the same
between the two patient groups (Table 1). Systemic hyper-
tension (treated) was more common in the transplant group
(84 of 90, 93%) than the CHF group (14 of 31, 45%) (p ,
0.0001). HMG-CoA reductase inhibitors were used in 53%
of posttransplant patients compared with 19% of CHF
controls (p , 0.001). Angiotensin-converting enzyme
(ACE) inhibitor therapy was administered to 100% of the
CHF controls versus 36% of posttransplant patients (p ,
0.0001).
Posttransplant clinical characteristics versus CAV status.
Time after transplantation ranged from 19 to 3,687 days
(X 5 1,538 6 892 days). The severity of CAV increased
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CAD 5 coronary artery disease
CAV 5 cardiac allograft vasculopathy
CHF 5 congestive heart failure
CMV 5 cytomegalovirus
HDL 5 high-density lipoprotein
ICUS 5 intracoronary ultrasound
LDL 5 low-density lipoprotein
NYHA 5 New York Heart Association
vWFAg 5 vonWillebrand factor antigen
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with the duration of the posttransplant period (Fig. 1). The
mean posttransplant duration was 1,186 6 869 days for the
non-CAV subgroup, 1,620 6 627 days for mild-CAV (p ,
0.05 vs. non-CAV) and 2,249 6 791 days for severe-CAV
(p , 0.01 vs. either non-CAV or mild-CAV subgroup). A
large range of posttransplant durations was noted within
each of the three CAV subgroups (Fig. 1).
There were no significant differences in age, gender,
pre-op CHF etiology, hypertension or diabetes mellitus
between the non-, mild- and severe-CAV subgroups (Table
2). There were no differences in the use of immunosuppres-
sive agents or ACE inhibitors. The use of HMG-CoA
reductase inhibitors tended to increase with severity of CAV
with 43% of non-CAV patients, 58% of mild-CAV patients
and 70% of severe-CAV patients on therapy. Cytomegalo-
virus (CMV) infections requiring treatment was most fre-
quent in mild-CAV. Mean donor heart ischemic time was
actually longest for the non-CAV group.
Atherogenic factors (Fig. 2 and 3). No statistical differ-
ences were found between the total cholesterol levels of
the posttransplant group (212 6 62 mg/dL), the CHF
controls (192 6 44 mg/dL) and the normal controls
(188 6 23 mg/dL). The mean HDL levels of the
posttransplant and CHF groups (39.4 6 12.1 mg/dL and
33.1 6 9.3 mg/dL, respectively) were statistically lower
than that of the normals (46.4 6 12 mg/dL). The mean
HDL level of the normal control subjects was statistically
higher than those of the mild- and severe-CAV sub-
groups but not different from the non-CAV subgroup.
The total cholesterol to HDL ratios for both transplanted
patients (5.9 6 2.6) and CHF controls (6.2 6 2.4) were
abnormally high and statistically comparable; both were
elevated compared with normal controls (4.3 6 1; both
p , 0.005). While mean apolipoprotein A levels for
transplant patients (127.4 6 29.1 mg/dL), CHF controls
(112.3 6 24.7 mg/dL) and normal controls (139.2 6
36.1 mg/dL) were all normal, the level for CHF patients
was statistically lowest (p , 0.05). There were no
differences in the mean LDL concentrations between
transplant patients, CAV subgroups, CHF controls and
normal subjects. There was a trend toward a higher mean
apolipoprotein B level in the transplanted patients
(114.2 6 25 mg/dL) compared with both CHF (105.4 6
22.9 mg/dL, p 5 0.08) and normal controls (102.2 6
19.1 mg/dL, p 5 0.07). Mean triglyceride concentrations
did not differ between the CHF (297 6 313) and
posttransplant (237 6 148) patients, but both were
significantly higher than that of the normal subjects
(110 6 59). There were no differences among the CAV
subgroups. The lipoprotein(a) level for the normal con-
trol group (12.8 6 11.3 mg/dL) was significantly lower
than that of either the CHF (33.3 6 34.8 mg/dL; p ,
0.05) or the transplant group (26.8 6 28.6 mg/dL; p ,
0.05), which were statistically similar. Mean Lp(a)
tended to be highest in the severe CAV subgroup
Figure 1. Severity of cardiac vasculopathy relative to time after cardiac
transplantation. , 5 median.
Table 1. Baseline Characteristics of the Patient Groups
Normal Controls (n 5 18) CHF Subjects (n 5 31) Transplant Patients (n 5 90)
Age 48.2 (46) 6 11 yrs 48.5 (50) 6 8.8 yrs 51.9 (54) 6 11.5 yrs*
Gender
Male 11 (61%) 25 (81%) 67 (74%)
Female 7 (39%) 6 (19%) 23 (26%)
CHF Etiology
Ischemic 15 (48%) 40 (44%)†
Nonischemic 16 (52%) 50 (56%)†
Hypertension‡ 14 (45%) 84 (93%)*
Diabetes mellitus 8 (26%) 16 (18%)
Statin Rx 6 (19%) 48 (53%)*
ACE Inhibitor Rx 31 (100%) 32 (36%)*
Creatinine, serum 0.9 (0.9) 6 0.2 mg/dL 1.2 (1.2) 6 0.4 mg/dL§ 1.8 (1.6) 6 0.7 mg/dL*\
Continuous variables expressed as mean (median) 6 1 SD.
*p , 0.05 for transplant patients versus CHF controls; †pretransplant etiology; ‡defined as need for treatment ($140/90 mm Hg). Posttransplant period in transplant patients;
§p , 0.005 for CHF controls versus normal controls; \p , 0.0005 for transplant patients versus normal controls.
ACE 5 angiotensin-converting enzyme; Rx 5 treatment; Statin 5 HMG-CoA reductase inhibitor.
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compared with non-CAV (p 5 0.06) and the mild CAV
(p 5 0.07).
Figure 3 depicts the renin, fibrinogen, vWFAg and
homocysteine data. Plasma renin activity was lowest for
normal controls (0.6 6 0.4 ng/mL/h), highest for CHF
controls (16.3 6 12.6 ng/mL/h; p , 0.05) and elevated
above normal for the transplanted patients (4.48 6 5.9
ng/mL/h; p 5 0.0001 vs. normal or CHF controls).
Fibrinogen levels in transplanted patients (412.1 6 85.9
mg/dL) and in the CHF subjects (428.3 6 76.3 mg/dL)
were elevated and statistically higher compared with the
normal controls (247 6 26.7 mg/dL, both p , 0.0001).
Mean vWFAg levels for the transplanted (207.9 6 65%)
and CHF groups (209.5 6 100%) were statistically similar
and elevated above that of the normals (113.1 6 44.2%,
both p , 0.0005).
The mean homocysteine level for normal controls was
within normal limits (9.2 6 2.2 mmol/L) and was
significantly lower than that of either the transplanted or
CHF group (both p 5 0.0001 vs. normal) (Fig. 3). It
appears that the homocysteine elevation in the CHF and
transplant groups is somewhat related to their decreased
renal function with an r 5 0.60 (p , 0.0001) between
serum creatinine and homocysteine levels. Tables 3 and 4
present the Vitamin B12 and folate levels for the study
groups.
DISCUSSION
Compared with normal subjects, posttransplant patients
have higher total cholesterol to HDL ratios and elevated
plasma levels of triglycerides, Lp(a), homocysteine,
vWFAg, fibrinogen and renin activity and lower HDL
levels. However, a striking finding of this study was that
many of these factors were already abnormal in the CHF
control patients, irrespective of whether their underlying
diagnosis was ischemic cardiomyopathy or nonischemic
dilated cardiomyopathy. This indicates that CHF patients
probably come to heart transplant already burdened with
many atherogenic factors rather than simply acquiring them
as a result of immunosuppressive therapy.
Clinical risk factors and variables. The clinical variables
of age, gender, pretransplant cardiac diagnosis, hyperten-
sion, diabetes mellitus, donor age and number of rejection
episodes were not associated with CAV severity. Donor age
was quite young, and it is doubtful that native CAD had a
significant influence on the presence or severity of CAV.
Donor ischemic time was actually longest for the non-CAV
subgroup; other studies also found little relationship of this
variable to CAV (24,25).
Consistent with previous reports (25–27), the finding of
CMV in urine, blood or tissue or CMV requiring therapy
tended to be related to CAV. However, in this study, the
association appeared most applicable to the mild CAV
Table 2. Status of Coronary Arteries and Clinical Characteristics of the Cardiac Transplantation Population
Characteristic
Coronary Artery Status
Non-CAV (n 5 46) Mild CAV (n 5 24) Severe CAV (n 5 20)
Age 52.4 (55) 6 11.1 yrs 52.2 (53) 6 11.2 yrs 50.3 (52.5) 6 13.1 yrs
Gender
Male 13 (28%) 7 (29%) 3 (15%)
Female 33 (72%) 17 (71%) 17 (85%)
Pretransplant Cardiac Diagnosis
Ischemic 22 (48%) 11 (46%) 7 (35%)
Dilated 24 (52%) 13 (54%) 13 (65%)
Hypertension 41 (89%) 24 (100%) 19 (95%)
Diabetes mellitus 7 (15%) 5 (21%) 4 (20%)
Time after transplantation 1,186 (946) 6 869 days 1,620 (1,733) 6 627 days* 2,249 (2,248) 6 177 days†‡
(See Fig. 1)
Donor age (yrs) 25.7 (23) 6 10.4 yrs 25.7 (25) 6 7.3 yrs 28.2 (23) 6 10.9 yrs
Ischemic time (min) 139.6 (135) 6 41.3 min 108.2 (103) 6 36.6 min 114.4 (114) 6 40 min†
# Rejection episodes ($3a) 0.72 (0.5) 6 0.91 0.91 (0) 6 1.2 0.7 (0) 6 1.1
CMV Infection ($1) 14 (30%) 15 (63%)* 9 (45%)
Creatinine, serum 1.7 (1.6) 6 0.5 mg/dL 1.6 (1.6) 6 0.3 mg/dL 2 (1.55) 6 1.3 mg/dL
Medication§
Cyclosporin 45/46 23/24 20/20
Dose 342 (300) 6 163.8 mg 312 (300) 6 136.1 mg 310 (300) 6 159.2 mg
Immuran 44/46 18/24 16/20
Dose 116 (125) 6 48.5 mg 107 (113) 6 54.8 mg 127 (125) 6 51.2 mg
Prednisone 17/46 9/24 11/20
Dose 5.6 (5) 6 2.7 mg 4.7 (5) 6 2 mg 6.4 (5) 6 4.2 mg
Statin Rx 20 (43%) 14 (58%) 14 (70%)†
ACE Inhibitor Rx 19 (41%) 6 (25%) 7 (35%)
Continuous variables expressed as mean (median) 6 1 SD.
*p , 0.05 of non-CAV versus mild CAV; †p , 0.05 of non-CAV versus severe CAV; ‡p , 0.05 of mild CAV versus severe CAV; §mean daily dose at most recent annual
evaluation.
ACE 5 angiotensin-converting enzyme; CAV 5 cardiac allograft vasculopathy; CMV 5 cytomegalovirus; Rx 5 treatment; Statin 5 HMG-CoA reductase inhibitor.
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subgroup; it is possible that the moderate-severe CAV
subgroup was reduced in size by the selective dropout of
“CMV patients” with graft failure and death.
Blood-plasma atherogenic markers. More transplant pa-
tients received “statins” compared with the CHF patients,
and the use was highest in severe CAV. Progressive CAV
still developed in these patients and likely started before
treatment was initiated. That is to say, few of the severe
CAV patients received statins long-term. A newly trans-
planted patient would now routinely be treated by one of
these agents, based on a report by Kobashigawa et al. (28)
showing clinical benefit with long-term pravastatin. The
favorable effect of statins in the posttransplant course is
likely related, in part, to their cholesterol-lowering proper-
ties (28–30). High-density lipoprotein levels were lowest in
the CHF group with intermediate values noted in the
transplant population. The highest posttransplant HDL
levels were noted in the non-CAV subgroup; although a
chance occurrence cannot be excluded, it is reasonable to
suggest that the elevated HDL in this subgroup was
protective for CAV.
Homocysteine’s role as a risk factor for atherosclerosis
(premature coronary and peripheral vascular disease) is
being established (31–37). Our data confirm the presence of
elevated plasma homocysteine levels after cardiac transplan-
tation (38) (Fig. 3). Based on the increased levels in the
CHF control group and the correlation with renal function,
this elevation is unlikely to be solely attributable to trans-
plantation and posttransplant therapy. The finding of ab-
normal homocysteine metabolism (and the other risk factors
noted) in NYHA class III to IV CHF patients is of clinical
importance with respect to whether some of these condi-
tions should be treated before transplantation.
Select vitamin deficiency is associated with increased
homocysteine levels (39–44). As a group, the transplant
patients had the highest serum folate and vitamin B12
concentrations, levels higher than those of the CHF con-
trols without any difference in their elevated homocysteine
levels. These findings are, in part, the result of aggressive
vitamin supplementation in our transplanted patients. It is
possible that the homocysteine concentration in our trans-
planted group would be still higher without vitamin sup-
plementation and the elevated vitamin B12 and folate levels.
Homocysteine levels can be elevated even when serum B12
and folate levels are in the normal range (42,45,46). The
data of this report cannot exclude the possibility that
Figure 2. Lipid studies of the three patient groups and CAV subgroups. Open diamond 5 normal controls; closed square 5 control-ischemic; open
square 5 control-dilated; open circle 5 non-CAV; closed circle 5 severe CAV; dotted line 5 normal value for laboratory; X 5 mild CAV; < 5 median.
CAV 5 cardiac allograft vasculopathy; CHF 5 congestive heart failure; HDL 5 high-density lipoprotein.
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transplant and CHF patients could have a “relative” vitamin
deficiency with higher requirements. The presence and
increased severity of CAV were associated with lower levels
of RBC folate (Table 3), despite similarly elevated levels of
homocysteine in the three CAV subgroups. High or high-
normal levels of RBC folate may also be necessary to be
adequately protective in this setting, providing a rationale
for the use of pharmacological doses of folate supplemen-
tation after transplantation (47–50).
Both fibrinogen and vWFAg were elevated in the post-
transplant group. It is quite possible that elevated levels of
these proteins over time contribute to the development of
CAV. vonWillebrand factor antigen, mediating platelet
adhesion to injured endothelium or exposed subendothe-
lium plays a critical role in the development of vascular
disease (51,52); whether this pertains to the development of
CAV in humans remains to be proven. Nevertheless,
platelet aggregation appears to be enhanced in posttrans-
Figure 3. Plasma homocysteine levels and potential atherogenic peptides and proteins for the three patient groups and CAV subgroups. Open diamond 5
normal controls; closed square 5 control-ischemic; open square 5 control-dilated; open circle 5 non-CAV; closed circle 5 severe CAV; dotted line 5
normal value for laboratory; X 5 mild CAV; < 5 median. CAV 5 cardiac allograft vasculopathy; CHF 5 congestive heart failure.
Table 3. Vitamin B12 and Folate Determination of the Study Groups
Vitamin Normal Controls CHF Controls Transplant Patients
Vitamin B12 400 (411) 6 209 pg/mL 524 (475) 6 203 pg/mL* 565 (514) 6 227 pg/mL†
Folate (RBC) 414 (397) 6 129 ng/mL 385 (391) 6 123 ng/mL 526 (476) 6 273 ng/mL‡
Folate (Serum) 14.4 (13.9) 6 4.8 ng/mL 12.3 (10.6) 6 5.7 ng/mL 15.6 (20) 6 5.8 ng/mL‡
*p , 0.005 for CHF controls versus normal controls; †p , 0.05 for transplant patients versus normal controls; ‡p , 0.01 for
transplant patients versus CHF controls.
CHF 5 congestive heart failure.
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plant patients (53,54). Platelets also appear to be an integral
part of the inflammatory process and may directly initiate an
inflammatory response of the vessel wall (55).
The observation of elevated vWFAg in the NYHA class
III to IV CHF population is also a major finding of this
investigation. It has been postulated that the “low-flow”
state of CHF can lead to intermittent or chronic, usually
subclinical, systemic or subendocardial ischemia, which
could evoke formation and destruction of microthrombi
with elevated vWFAg as a marker. It is also possible that
this elevation represents a link between hypoperfusion,
coagulation, inflammation and cytokine release in this
setting.
Although controversial, renin may be a vasculopathic
substance (56,57). Mean circulating plasma renin activity
was elevated in our posttransplant group (without CAV
subgroup differences) compared with the normal controls.
Some of the elevation in both CHF and transplant groups
is attributable to ACE inhibitor therapy.
Study limitations. It is possible that our population was
influenced by deaths (albeit a small number) of patients as
they proceeded into the period more remote from trans-
plant; the resultant population may, therefore, have evolved
into a “healthier” cohort. In addition, this was a cross-
sectional study of transplanted patients residing at various
time-points after transplant rather than a sequential study,
which would allow each patient to serve as his or her own
pretransplant control with longitudinal data acquisition
during the posttransplant course. Nevertheless, our CHF
control group provided a pretransplant reference population
with important findings that are abnormal, clinically rele-
vant and merit further study.
Conclusions. In addition to systemic hypertension and
potentially vasculopathic medications, postcardiac trans-
plant patients are exposed to a number of atherogenic and
vasculopathic factors including elevated total cholesterol/
HDL cholesterol ratio, triglycerides, Lp(a), homocysteine,
vWFAg, fibrinogen and renin with a reduced HDL cho-
lesterol. It is likely that many of these factors contribute to
the development of CAV with coronary occlusion, a major
cause of graft failure and death after heart transplantation.
The observation that many of these atherogenic-
vasculopathic markers are already present in CHF patients
pretransplantation raises the question of whether the treat-
able factors should be therapeutically approached (e.g.,
statin therapy, vitamin supplementation) before cardiac
transplantation.
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